Your browser does not allow JavaScript!
JavaScript is necessary for the proper functioning of this website. Please enable JavaScript or use a modern browser.
Repository of the University of Ljubljana
Open Science Slovenia
Open Science
DiKUL
slv
|
eng
Search
Advanced
New in RUL
About RUL
In numbers
Help
Sign in
Details
The role of focal adhesion kinase in bladder cancer : translation from in vitro to ex vivo human urothelial carcinomas
ID
Markovič, Gaja
(
Author
),
ID
Resnik, Nataša
(
Author
),
ID
Janev, Aleksandar
(
Author
),
ID
Zupančič, Daša
(
Author
),
ID
Grubelnik, Gašper
(
Author
),
ID
Smrkolj, Tomaž
(
Author
),
ID
Erdani-Kreft, Mateja
(
Author
),
ID
Debeljak, Maruša
(
Author
),
ID
Čemažar, Maja
(
Author
),
ID
Jesenko, Tanja
(
Author
),
ID
Omerzel, Maša
(
Author
)
PDF - Presentation file,
Download
(2,17 MB)
MD5: A5DE935112BCBAD422671A7C931BE3C9
URL - Source URL, Visit
https://reference-global.com/article/10.2478/raon-2025-0052
Image galllery
Abstract
Background: Focal adhesion kinase (FAK), a cytoplasmic tyrosine kinase, plays a crucial role in focal adhesion turnover by interfacing between the extracellular space, transmembrane integrins, and actin filaments. Its significance for the progression of several malignancies, including bladder cancer, has been well-documented. However, its precise role and the implications of its inhibition in bladder cancer tissues and urothelial in vitro models has not been fully explored. This study examined FAK expression and function in human bladder cancer biopsies and in vitro bladder cancer models. Materials and methods: Ex vivo analyses were performed using reverse transcription-quantitative PCR (qRT-PCR), western blotting, and immunohistochemistry to compare FAK expression between bladder cancer tissues and adjacent normal tissues. In vitro, FAK expression was assessed in low-grade (LG) human non-invasive papilloma urothelial cell line RT4 for NMIBC (Ta), high-grade (HG) human muscle-invasive cancer urothelial cell line T24 for MIBC (T2) and normal porcine urothelial (NPU) cells using qRT-PCR and western blotting, as well as flow cytometry for the quantification of FAK-positive RT4 and T24 cells. The role of FAK in cancer cell survival was explored in vitro using microRNA (miRNA) to silence FAK expression. Additionally, we used FAK inhibitors PND-1186, PF-573228 and defactinib to investigate the effects of FAK inhibition on normal compared to cancerous bladder urothelial cells. Results: Ex vivo analyses demonstrated significantly higher FAK expression in bladder cancer tissues compared to adjacent normal tissues. Similarly, in vitro analyses showed significantly higher FAK expression in RT4 and T24 cells than NPU cells. Silencing FAK using anti-FAK plasmids led to increased caspase-3-mediated apoptosis of RT4 and T24 cells and growth reduction of stably transfected T24 cells. Importantly, based on cell viability assays, treatment with 100 μM defactinib for 2 hours per day on 3 consecutive days was identified as a clinically relevant regimen. Under this treatment, the viability of differentiated NPU cells remained high at 108.4 ± 17.1%, while the viability of 2-day RT4 and 2-day T24 cells was drastically reduced to 4.1 ± 2.7% and 7.6 ± 2.9%, respectively. Conclusions: To our knowledge, this is the first report demonstrating the role of FAK and its inhibition across both normal and cancerous bladder urothelial models. This study highlights the critical role of FAK in the progression of human bladder cancer and establishes a foundation for exploring FAK inhibition as a potential therapeutic approach in bladder cancer treatment.
Language:
English
Keywords:
bladder cancer
,
defactinib
,
focal adhesion kinase
,
human urothelial carcinoma
,
urothelial cell
Work type:
Article
Typology:
1.01 - Original Scientific Article
Organization:
MF - Faculty of Medicine
Publication status:
Published
Publication version:
Version of Record
Year:
2025
Number of pages:
Str. 349-367
Numbering:
Vol. 59, iss. 3
PID:
20.500.12556/RUL-176793
UDC:
616.6-006
ISSN on article:
1318-2099
DOI:
10.2478/raon-2025-0052
COBISS.SI-ID:
251661571
Publication date in RUL:
16.12.2025
Views:
222
Downloads:
67
Metadata:
Cite this work
Plain text
BibTeX
EndNote XML
EndNote/Refer
RIS
ABNT
ACM Ref
AMA
APA
Chicago 17th Author-Date
Harvard
IEEE
ISO 690
MLA
Vancouver
:
Copy citation
Share:
Record is a part of a journal
Title:
Radiology and oncology
Shortened title:
Radiol. oncol.
Publisher:
Slovenian Medical Society - Section of Radiology, Croatian Medical Association - Croatian Society of Radiology
ISSN:
1318-2099
COBISS.SI-ID:
32649472
Licences
License:
CC BY 4.0, Creative Commons Attribution 4.0 International
Link:
http://creativecommons.org/licenses/by/4.0/
Description:
This is the standard Creative Commons license that gives others maximum freedom to do what they want with the work as long as they credit the author.
Secondary language
Language:
Slovenian
Keywords:
rak mehurja
,
defaktinib
,
fokalna dhezijska kinaza
,
humani urotelialni karcinom
,
urotelijska celica
Projects
Funder:
ARIS - Slovenian Research and Innovation Agency
Project number:
P3-0108
Name:
Celična biologija in molekularna genetika v biomedicini
Funder:
ARIS - Slovenian Research and Innovation Agency
Project number:
P3-0003
Name:
Razvoj in ovrednotenje novih terapij za zdravljenje malignih tumorjev
Funder:
ARIS - Slovenian Research and Innovation Agency
Project number:
J7-2594
Name:
Uporaba amnijske membrane za inovativno multimodalno zdravljenje bakterijskega cistitisa in raka sečnega mehurja: učinek njene protimikrobne, imunomodulatorne in protirakave aktivnosti
Funder:
ARIS - Slovenian Research and Innovation Agency
Project number:
J3-2521
Name:
Vnetni proces pri intersticijskem cistitisu in ovrednotenje delovanja agonistov kanabinoidnih receptorjev sečnega mehurja – od celic do pacienta
Funder:
ARIS - Slovenian Research and Innovation Agency
Project number:
MRIC UL IP-0510
Name:
Mreža raziskovalnih infrastrukturnih centrov
Similar documents
Similar works from RUL:
Similar works from other Slovenian collections:
Back